CM Management’s Relmada Therapeutics RLMD Stock Holding History

CM Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,000	Closed	-$405K	–	74
2022 Q1	$405K	Buy	15,000 +5,000	+50%	+$103K	0.34%	68
2021 Q4	$225K	Buy	+10,000	New	+$222K	0.17%	84

Other funds holding RLMD

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

CM Management's RLMD Position: Q2 2022 in Review

CM Management sold out of Relmada Therapeutics (RLMD) in Q2 2022, closing a stake of 15,000 shares — an estimated $405K sold.

CM Management first reported a position in RLMD in Q4 2021 and held it in 2 quarters. The position peaked at $405K in Q1 2022. 113 funds tracked by Wall St. Rank hold RLMD as of Q2 2022.

CM Management reported no remaining Relmada Therapeutics position as of Q2 2022 after selling out during the quarter.
CM Management sold 15,000 Relmada Therapeutics shares in Q2 2022, an estimated $405K.
CM Management first reported a position in Relmada Therapeutics in Q4 2021 and held it in 2 quarters.
CM Management's Relmada Therapeutics position peaked at $405K in Q1 2022.
113 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2022.

Based on CM Management's 13F filing for Q2 2022, filed 8 Aug 2022.